Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients

J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):170-2. doi: 10.1097/QAI.0b013e31823e6518.

Abstract

From the Italian Antiretroviral Resistance Cohort Analysis database, 1104 patients starting ritonavir-boosted darunavir-containing regimen were included as follows: 118 subsequently failed treatment at a median of 11 months (interquartile range: 5-20); 3 years failure proportion: 24.6%. HIV Drug Resistance Database and ANRS interpretation algorithms were associated with a progressive risk prediction of virological failure at adjusted Cox. In contrast, Rega algorithm allows to identify a higher number of patients at risk of failure, without losing statistical significance. Four mutations (V32I, I50V, L76V, I84V) were predictive of failure, the hazard ratio progressively increased by detecting 1 (hazard ratio: 2.0, 95% confidence interval: 1.3 to 3.0), 2 (3.6, 2.0 to 6.6), or 3 of them (9.7, 2.8 to 33.5).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Algorithms
  • Antiretroviral Therapy, Highly Active
  • Darunavir
  • Drug Resistance, Multiple, Viral / genetics*
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / genetics
  • HIV Protease Inhibitors / therapeutic use*
  • HIV-1 / drug effects*
  • Humans
  • Italy
  • Male
  • Middle Aged
  • Mutation*
  • Risk Factors
  • Ritonavir / therapeutic use*
  • Sulfonamides / therapeutic use*
  • Treatment Failure

Substances

  • HIV Protease Inhibitors
  • Sulfonamides
  • Ritonavir
  • Darunavir